21 September 2016 EMA/246932/2013

Telematics Enterprise Architecture Board Terms of reference

The European Union Telematics Enterprise Architecture Board is the information technology architecture governance body that operates on behalf of the European Medicines Regulatory Network. In this context, the Network comprises the European Medicines Agency (EMA), the network of EU national competent authorities as represented by the Heads of Medicines Agencies (HMA), and the European Commission, as represented by DG SANCO. The high-level mandate of the Telematics Enterprise Architecture Board is to: 

Define the EU Telematics Enterprise Architecture (both as is and to be) referring major strategic issues as necessary



Provide Enterprise Architecture advice to the IT Directors and EU TMB



Check compliance of projects delivered by project teams and maintenance activities

The Board reports to the IT Directors Group represented by its Executive Committee. 1. Composition 1.1

The Board consists of: 

The EMA CTO



Five representatives of five distinct National Competent Authorities nominated by HMA



Three EMA representatives



One European Commission representative (ISA DIGIT).

1.2

The Board is chaired by the CTO of EMA.

1.3

The Board members are appointed for a three year period (renewable) or until such time as they no longer represent the organisation which they represented on appointment. Should a member be unable to attend meetings for a continuous period of 12 months, their membership shall terminate.

1.4

No substitution for members unable to attend the meeting will be accepted.

1.5

The Board will be supported by the Telematics PMO and the Telematics Secretariat.

2. The role of the Board includes: 2.1

Facilitating and stimulating interoperability between the systems and IT environments of EMA, the National Competent Authorities and the Commission (the Network), taking into account the differences of capacity to adapt among the partners of the network in order to be as inclusive as possible.

2.2

Promoting cost efficiency, simplicity and transparency in design and development of IT solutions for the network.

2.3

Proposing standards approaches and, where appropriate, solutions to the Network in order to allow the partners involved in this Network to benefit from: 

Re-use by all the interested parties of existing systems or services in any of the partner's (or groups of partners) systems’ catalogues



Avoidance of duplicated efforts for a single function within the network



Mutualisation of functions of general interest for the Network (implementation e.g. development of business and IT solutions of common interest, shared reference resources, coordinated data dissemination, services, etc.)



Better and effective exchange of data across the Network



Interoperability of the Network's common core business processes with domains in which not all the participants across the Network currently have a remit (e.g. Medical Devices)



Bringing technical expertise to the Network to reach the above objectives.



Encouraging adoption of the EA solutions within the Network.

In order to reach these objectives, the Enterprise Architecture Board will define, agree or undertake the following activities: 2.4

Document the AS-IS situation.

2.5

Propose and develop a Target Enterprise Architecture for the Network covering strategy, business, systems and data, aligned to the future needs and opportunities of the Network's members and needs.

2.6

Propose and develop a roadmap to achieve the Target Enterprise Architecture, including a short-term, cost effective Baseline Enterprise Architecture for the Network covering strategy, business, basic systems and data, aligned to the needs and opportunities of the Network's members and needs.

2.7

Prepare and submit for adoption a multi-annual Enterprise Architecture programme to the IT Directors; this programme will be updated and re-submitted annually.

2.8

Report the progress of the EA programme to the IT Directors Meeting.

2.9

Advise the IT Directors Meeting and the IT Directors Executive Group on interoperability and use of services issues and opportunities.

2.10

Be consulted prior to the start of each new project (at draft Vision document stage) proposed or included in the Network in order to ensure the alignment of IT project with the Baseline and Target EA and avoid the occurrence of duplicate business functions (for cost efficiency and simplification reasons).

2.11

Identify and report non-compliance issues according to the Baseline Enterprise Architecture.

2.12

Advise the IT Directors Meeting on potential exception requests.

2.13

Respect the European Interoperability Framework principles.

2.14

Liaise with the EU ISA programme (Interoperability Solutions for European Public Administrations) in order to reuse any existing approaches, strategic choices or solutions.

3. Meetings 3.1

Meetings will be held monthly by teleconference and by face-to-face meetings as necessary.

3.2

Members of the Board will be reimbursed for travel and per- diem by the EMA in accordance with the Agency’s reimbursement rules.

3.3

Meetings are convened by the Board Chair or at the request of at least 3 members.

3.4

All documentation relating to the meeting will normally be circulated a minimum of 5 working days in advance of the meeting date.

3.5

Minutes of the meeting will be taken by the Secretariat and will normally be circulated to all members of the Board for comment within 2 weeks of the meeting date. Minutes shall be approved by written procedure.

3.6

The quorum for Board meetings is at least 66% of members. At least three representatives of NCAs and two representatives of EMA must be present in order for the meeting to be quorate.

3.7

Agreement shall be reached by consensus wherever possible. Where this is not possible, decisions shall be taken by simple majority vote. Proxy votes are accepted.

Telematics Enterprise Architecture Board - European Medicines Agency

... Telematics Enterprise Architecture Board is the information technology ... Re-use by all the interested parties of existing systems or services in any of the ...

109KB Sizes 8 Downloads 224 Views

Recommend Documents

EU Telematics Management Board - European Medicines Agency
EU Telematics Management Board - European Medicines Agencyfeedproxy.google.com/~r/EmaUpdates/~3/UOZtMxO1_G4/open_document.jsp

Telematics governance model - European Medicines Agency
Network. • The EU TMB reports and advises on IT related topics to the EMA ... EU Network Data Board (EU NDB). Role: ... 7 Service Delivery Managers (5 EMA.

European Union Network data board - European Medicines Agency
Sep 21, 2016 - EMA/231985/2016. European Union Network Data Board. Terms of Reference. 1. Remit, vision and mission. The European Union Network Data Board (EUNDB) is an advisory body co-chaired by the Head of. Business Data and Support Department (EM

Notice - European Medicines Agency
Apr 28, 2017 - 2. The United Kingdom will then become a 'third country'. 3. Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. In view of the considerable uncertainties, in parti

Report - European Medicines Agency
May 30, 2017 - Pharmaceutical companies are invited to present their pre-clinical data pertaining to ... patients per year, as many questions about the best use of ALK ... of knowledge and evidence to support the planning and regulatory.

Human Medicines Highlights Newsletter - European Medicines Agency
Mar 8, 2018 - Treatment of uterine fibroids. Haematology. New medicines authorised. • Adynovi (rurioctocog alfa pegol). Treatment and prevention of bleeding in patients with haemophilia A. New information on authorised medicines. • Feraccru (ferr

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Treatment of cystine crystal deposits in the eye. New information on authorised medicines. Lucentis (ranibizumab) - change in indication. Treatment of visual ...

Human Medicines Highlights Newsletter - European Medicines Agency
The new EudraVigilance system and the electronic reporting of individual case ... the ISO/ICH E2B(R3) format: hands-on training course - October 2017 ... granted a conditional marketing authorisation on the basis of less complete clinical data ...

Agenda - European Medicines Agency - europa.eu
4 days ago - EMA/CAT/426129/2018. Page 2/17. Table of contents. 1. Introduction. 5. 1.1. Welcome and declarations of interest of members, alternates and ...

Finasteride - European Medicines Agency - europa.eu
Apr 25, 2018 - Page 2/8. Product Name (in authorisation country). MRP/DCP. Authorisation number. National Authorisation Number. MAH of product in the.

Agenda - European Medicines Agency - europa.eu
Sep 8, 2016 - 3-year report on Pharmacovigilance activities. Helen Lee, European Commission. •. Scanning the horizon for 2016 – 2018. Peter Arlett, EMA.

Human medicines highlights newsletter - European Medicines Agency
PCWP and HCPWP joint meeting - Sept 2016 - meeting documents. • Workshop on identifying opportunities for 'big data' in medicines development and ...

Human Medicines Highlights Newsletter - European Medicines Agency
Used for the management of hypovolaemia (low blood volume) caused by acute (sudden) blood loss .... EMA's Business Continuity Plan for Brexit published.

Agenda - European Medicines Agency veterinary medicines ...
On arriving for your meeting at 30 Churchill Place, please report to reception where you will be issued with an access pass. This pass will allow you to enter our industry lounge, which you are welcome to utilise during your visit. The industry loung

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a ... Withdrawal of applications for new medicines .... fifth annual regulatory conference on optimising the development of advanced therapies to.

Veterinary medicines highlights 2016 - European Medicines Agency
Jan 26, 2017 - is an antiparasitic medicine that treats the Varroa mite infestation in honey-bee colonies, which is considered to be the most significant parasitic ...

Human Medicines Highlights Newsletter - European Medicines Agency
Implant used to help new bone develop in patients with spinal disc problems and leg fractures .... E-mail [email protected] Website www.ema.europa.eu.

Human Medicines Highlights Newsletter - European Medicines Agency
RSS feeds you need one of the following: a modern web browser; a web-based news reader or a desktop news reader. For a list of RSS readers please refer to ...

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

Agenda - European Medicines Agency - europa.eu
Jun 18, 2018 - 27. 7.8.1. List of all applications submitted/expected and the COMP coordinatorship distribution of .... 5,10-dihydrodibenzo[b,e][1,4] diazepin-11-one, EMA/OD/031/10 Glutathione-pegylated ...... Abbreviations / Acronyms.

Committee_Meeting dates_2017 - European Medicines Agency
Sep 26, 2016 - An agency of the European Union. Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555. Send a question via our website ...

Registration form - European Medicines Agency
Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc.

dexlansoprazole, lansoprazole - European Medicines Agency
European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 13 September 2017. EMA/727763/2017. Human Medicines Evaluation Division. List of nationally authorised medicinal products. Active substance(s): dexlansop